drugset
Drugs / 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots
last change Feb 2021 re-read 3 minutes ago

89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots

Diagnostic / imaging agent

Investigated by
Cornell University/Weill Cornell Medical Center · Memorial Sloan Kettering Cancer Center · National Cancer Institute (NCI)

Trials 1

today NCT04167969 · Ph 1
20212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04167969 Feb 2021 → Nov 2027 expected prostate cancer Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as (89Zr)-DFO-PSMAi-PEG-Cy5.5-C' dots “The purpose of this study is to see whether using the copper-64 (64Cu) or zirconium-89 (89Zr) radiolabeled PSMA-targeting C' dot tracer, termed 64Cu-NOTA-PSMAi-PEG-Cy5.5-C'...” NCT04167969 ↗
1

NCT04167969 ↗
Modality Diagnostic / imaging agent “copper-64 (64Cu) or zirconium-89 (89Zr) radiolabeled PSMA-targeting C' dot tracer” NCT04167969 ↗
Route Intravenous “Patients (up to 6) will receive an intravenous (IV) injection of approximately 5-7 mCi (+/- 10%) of PSMA-targeting C' dot tracer within 24-48 h before surgery.” NCT04167969 ↗